Germany moves to more than double drug rebates as U.S. biotech firms retreat into secrecy

The price of selling a branded medicine in Germany may soon rise sharply for drug companies. German lawmakers passed a bill that would increase the mandatory rebate, the fixed discount manufacturers must return to the country's public health insurance system as a condition of market access, from 7 percent to 15.5 percent. The bill has not yet cleared Germany's upper chamber.

What the German rebate change would mean

The German government framed the increase as a response to a sizable budget gap in the country's health insurance system. At 15.5 percent, the rebate would represent more than double what drugmakers currently hand back.

Industry groups were clear about their objection. They warned that if the bill clears the upper chamber, it would deter investment in Germany and put the country's access to new medicines at risk. Reuters reported on the passage. Those warnings are projections, and the upper chamber vote has not yet happened.

The distinction matters. A bill that passes one chamber is not a signed policy. What was passed is a proposal that would, if enacted, more than double a cost pharmaceutical companies already absorb as a condition of operating in the German market.

American biotech firms go quiet over China competition

A separate trend is reshaping how U.S. drug developers talk about their work. The Wall Street Journal reported that the rapid growth of China's biotech industry has pushed American startups to withhold nearly all public information about what they are doing.

U.S. companies are increasingly reluctant to publish early data. Some are refusing to disclose which diseases they are targeting. Others are keeping their scientific goals entirely private. The concern, as the Journal described it, is that nimble Chinese firms could take that information and move quickly to develop competing drugs, beating American companies to the start of clinical trials.

A clinical trial is the structured, regulated study a company must complete to demonstrate that a drug is safe and effective before seeking regulatory approval. Getting there first carries real competitive weight, which the Journal describes as the core reason for this posture of near-total secrecy.

The Journal did not name specific firms operating this way, but described the behavior as increasingly common among U.S. startups. The practice of sharing early scientific data, long a default in American biotech, is giving way to competitive caution driven by the pace of Chinese drug development.